Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
OBJECTIVETo assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance. METHODSTwo open-label trials in adult participants with relapsing multiple sclerosis were...
Gespeichert in:
Veröffentlicht in: | Neurology 2018-03, Vol.90 (11), p.e955-e962 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e962 |
---|---|
container_issue | 11 |
container_start_page | e955 |
container_title | Neurology |
container_volume | 90 |
creator | Chataway, Jeremy Martin, Keith Barrell, Kevin Sharrack, Basil Stolt, Pelle Wraith, David C |
description | OBJECTIVETo assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance.
METHODSTwo open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions.
RESULTSIn study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies.
CONCLUSIONRelatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted.
CLASSIFICATION OF EVIDENCEThis work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions. |
doi_str_mv | 10.1212/WNL.0000000000005118 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2007419107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2007419107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4988-b65c6d5e0442f9c1be9d72df189c392e27ca36d3985ed5d30838807cc4e50ce93</originalsourceid><addsrcrecordid>eNqFkE9P3DAQxS1EBcufb1AhH7mYzthObB8RghZp20otFdyirDNhA84m2ElXfPtmtVBVPcBcRpr3ezOjx9hHhDOUKD_dfpufwT-VIdodNsNM5iJX8m6XzQCkFcoau88OUnoAmETj9ti-dDo3CsyM_bisa_JD4l3Nz2_uxNefAieNN207rrphSbHsn3n3myLHnK-JHhNvVjxSKPvUrO55O4ah6QPx5APFLjXpiH2oy5Do-KUfsl9XlzcXX8T8--fri_O58NpZKxZ55vMqI9Ba1s7jglxlZFWjdV45SdL4UuWVcjajKqsUWGUtGO81ZeDJqUN2ut3bx-5ppDQUbZM8hVCuqBtTIQGMRodgJlRvUT99mCLVRR-btozPBUKxSbOY0iz-T3OynbxcGBctVX9Nr_FNgN0C6y4MFNNjGNcUiyWVYVi-t1u_Yd1gOaIWEtCCQgVimiCqP5uwjwc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007419107</pqid></control><display><type>article</type><title>Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis</title><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Chataway, Jeremy ; Martin, Keith ; Barrell, Kevin ; Sharrack, Basil ; Stolt, Pelle ; Wraith, David C</creator><creatorcontrib>Chataway, Jeremy ; Martin, Keith ; Barrell, Kevin ; Sharrack, Basil ; Stolt, Pelle ; Wraith, David C ; ATX-MS1467 Study Group ; ATX-MS1467 Study Group ; For the ATX-MS1467 Study Group</creatorcontrib><description>OBJECTIVETo assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance.
METHODSTwo open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions.
RESULTSIn study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies.
CONCLUSIONRelatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted.
CLASSIFICATION OF EVIDENCEThis work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000005118</identifier><identifier>PMID: 29467307</identifier><language>eng</language><publisher>United States: American Academy of Neurology</publisher><ispartof>Neurology, 2018-03, Vol.90 (11), p.e955-e962</ispartof><rights>2018 American Academy of Neurology</rights><rights>2018 American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4988-b65c6d5e0442f9c1be9d72df189c392e27ca36d3985ed5d30838807cc4e50ce93</citedby><cites>FETCH-LOGICAL-c4988-b65c6d5e0442f9c1be9d72df189c392e27ca36d3985ed5d30838807cc4e50ce93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29467307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chataway, Jeremy</creatorcontrib><creatorcontrib>Martin, Keith</creatorcontrib><creatorcontrib>Barrell, Kevin</creatorcontrib><creatorcontrib>Sharrack, Basil</creatorcontrib><creatorcontrib>Stolt, Pelle</creatorcontrib><creatorcontrib>Wraith, David C</creatorcontrib><creatorcontrib>ATX-MS1467 Study Group</creatorcontrib><creatorcontrib>ATX-MS1467 Study Group</creatorcontrib><creatorcontrib>For the ATX-MS1467 Study Group</creatorcontrib><title>Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis</title><title>Neurology</title><addtitle>Neurology</addtitle><description>OBJECTIVETo assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance.
METHODSTwo open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions.
RESULTSIn study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies.
CONCLUSIONRelatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted.
CLASSIFICATION OF EVIDENCEThis work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions.</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkE9P3DAQxS1EBcufb1AhH7mYzthObB8RghZp20otFdyirDNhA84m2ElXfPtmtVBVPcBcRpr3ezOjx9hHhDOUKD_dfpufwT-VIdodNsNM5iJX8m6XzQCkFcoau88OUnoAmETj9ti-dDo3CsyM_bisa_JD4l3Nz2_uxNefAieNN207rrphSbHsn3n3myLHnK-JHhNvVjxSKPvUrO55O4ah6QPx5APFLjXpiH2oy5Do-KUfsl9XlzcXX8T8--fri_O58NpZKxZ55vMqI9Ba1s7jglxlZFWjdV45SdL4UuWVcjajKqsUWGUtGO81ZeDJqUN2ut3bx-5ppDQUbZM8hVCuqBtTIQGMRodgJlRvUT99mCLVRR-btozPBUKxSbOY0iz-T3OynbxcGBctVX9Nr_FNgN0C6y4MFNNjGNcUiyWVYVi-t1u_Yd1gOaIWEtCCQgVimiCqP5uwjwc</recordid><startdate>20180313</startdate><enddate>20180313</enddate><creator>Chataway, Jeremy</creator><creator>Martin, Keith</creator><creator>Barrell, Kevin</creator><creator>Sharrack, Basil</creator><creator>Stolt, Pelle</creator><creator>Wraith, David C</creator><general>American Academy of Neurology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180313</creationdate><title>Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis</title><author>Chataway, Jeremy ; Martin, Keith ; Barrell, Kevin ; Sharrack, Basil ; Stolt, Pelle ; Wraith, David C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4988-b65c6d5e0442f9c1be9d72df189c392e27ca36d3985ed5d30838807cc4e50ce93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chataway, Jeremy</creatorcontrib><creatorcontrib>Martin, Keith</creatorcontrib><creatorcontrib>Barrell, Kevin</creatorcontrib><creatorcontrib>Sharrack, Basil</creatorcontrib><creatorcontrib>Stolt, Pelle</creatorcontrib><creatorcontrib>Wraith, David C</creatorcontrib><creatorcontrib>ATX-MS1467 Study Group</creatorcontrib><creatorcontrib>ATX-MS1467 Study Group</creatorcontrib><creatorcontrib>For the ATX-MS1467 Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chataway, Jeremy</au><au>Martin, Keith</au><au>Barrell, Kevin</au><au>Sharrack, Basil</au><au>Stolt, Pelle</au><au>Wraith, David C</au><aucorp>ATX-MS1467 Study Group</aucorp><aucorp>ATX-MS1467 Study Group</aucorp><aucorp>For the ATX-MS1467 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2018-03-13</date><risdate>2018</risdate><volume>90</volume><issue>11</issue><spage>e955</spage><epage>e962</epage><pages>e955-e962</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>OBJECTIVETo assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance.
METHODSTwo open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions.
RESULTSIn study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies.
CONCLUSIONRelatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted.
CLASSIFICATION OF EVIDENCEThis work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions.</abstract><cop>United States</cop><pub>American Academy of Neurology</pub><pmid>29467307</pmid><doi>10.1212/WNL.0000000000005118</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3878 |
ispartof | Neurology, 2018-03, Vol.90 (11), p.e955-e962 |
issn | 0028-3878 1526-632X |
language | eng |
recordid | cdi_proquest_miscellaneous_2007419107 |
source | Journals@Ovid Complete; Alma/SFX Local Collection |
title | Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A03%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20ATX-MS-1467%20immunotherapy%20over%2016%20weeks%20in%20relapsing%20multiple%20sclerosis&rft.jtitle=Neurology&rft.au=Chataway,%20Jeremy&rft.aucorp=ATX-MS1467%20Study%20Group&rft.date=2018-03-13&rft.volume=90&rft.issue=11&rft.spage=e955&rft.epage=e962&rft.pages=e955-e962&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000005118&rft_dat=%3Cproquest_cross%3E2007419107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007419107&rft_id=info:pmid/29467307&rfr_iscdi=true |